If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() FEMS Yeast ResearchVolume 6 Issue 4, Pages 558 - 566 Special Issue: Cryptococcus the once-sleeping giant is fully awake Published Online: 26 Apr 2006 © 2010 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved Published on behalf of the Federation of European Microbiological Societies
Abstract | References | Full Text: HTML, PDF (Size: 222K) | Related Articles | Citation Tracking MINIREVIEW Application of proton nuclear magnetic resonance spectroscopy to the study of Cryptococcus and cryptococcosis Copyright © 2006 Federation of European Microbiological Societies KEYWORDS
Cryptococcus
• cryptococcosis • nuclear magnetic resonance spectroscopy • diagnostics • species identification • virulence determinants ABSTRACTProton nuclear magnetic resonance spectroscopy is a nondestructive technique that identifies chemicals in solution and in living cells. It has been used in cryptococcal research to identify the primary structure of capsular glucuronoxylomannans, link cellular apoptosis susceptibility (CAS) genes to positioning of residues on the mannose backbone of glucuronoxylomannan, and verify that the cryptococcal virulence determinant, phospholipase B, is elaborated in vivo. Promising clinical applications include speciation (Cryptococcus neoformans and Cryptococcus gattii), with preliminary evidence that varieties neoformans and grubii can also be distinguished, non-invasive diagnosis of cerebral cryptococcomas, and, in cases of meningitis, monitoring therapeutic response by analysis of cerebrospinal fluid. Received 9 October 2005; revised 7 January 2006; accepted 8 January 2006. |